动脉硬性斑块稳定和回归:临床证据的审查
Ashish Sarraju1, Steven E Nissen2
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Nature reviews. Cardiology
|January 4, 2024
概括
降低LDL胆固醇可以显著降低动脉样硬化斑块负担. 需要新的疗法和非侵入性成像来解决LDL-C降低以外的剩余心血管风险,以稳定斑块.
科学领域:
- 心血管医学 心血管医学
- 医疗成像医学成像
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉硬化斑块是由脂质沉积,炎症和动脉损伤引起的.
- 通过他类药物和PCSK9抑制剂降低低密度脂蛋白胆固醇 (LDL-C),可以减少斑块负担.
- 尽管最大限度地降低了LDL-C,但残留心血管风险仍然存在.
研究的目的:
- 探索治疗方法,除了减少LDL-C外,还可以治疗剩余心血管风险.
- 调查新型成像在评估斑块稳定和回归中的作用.
- 为了评估个性化心血管管理的非侵入性斑块评估.
主要方法:
- 使用侵入性成像 (血管内超声波) 来评估斑块负担的临床试验的综述.
- 对降脂策略 (他类药物,PCSK9抑制剂) 的研究数据的分析.
- 探索当代非侵入性成像 (冠状动脉计算机断层扫描血管造影) 的斑块特征.
主要成果:
- 侵入性成像证实LDL-C降低安全降低斑块负担并修改组成.
- 新型降脂疗法在斑块回归和事件风险方面显示出渐进的好处.
- 非侵入性成像允许评估斑块负担和特征.
结论:
- 除了降低LDL-C之外的治疗策略对于斑块稳定和回归是必要的.
- 非侵入性成像具有研究新疗法和指导个性化管理的潜力.
- 需要进一步验证非侵入性斑块评估的临床应用.
相关概念视频
Inflammation
53.4K
Overview
53.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
665
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
665
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K


